Oral sotalol was given to 64 patients (78% postinfarction) with recurrent, reentrant ventricular tachycardia (VT) during an average follow-up period of 19.7 months. Fifty-nine (92%) patients had previously experienced recurrent ventricular tachycardia, in spite of having received an average of three
Efficacy of sotalol in controlling reentrant supraventricular tachycardias
β Scribed by R. N. Scott Millar
- Publisher
- Springer US
- Year
- 1990
- Tongue
- English
- Weight
- 443 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0920-3206
No coin nor oath required. For personal study only.
β¦ Synopsis
Sotalol is unique among beta-blocking agents having significant Class III antiarrhythmic action. In a series of 22 patients with Wolff-Parkinson-White (WPW) syndrome and seven patients with atrioventricular nodal reentry tachycardia (AVNRT) resistant to multiple drugs, sotalol was studied by acute electrophysiologic means, as well as by long-term clinical follow-up ranging from 1 to 47 months. Sustained reciprocating tachycardia was rendered noninducible in 13 of 18 patients with WPW and in 5 of 6 with AVNRT. Long-term control of symptomatic tachycardia was achieved in 77% of patients with WPW and in 57% of patients with resistant AVNRT. Side effects were those associated with beta blockade. Two patients developed ventricular irritability associated with excessive QT prolongation.
π SIMILAR VOLUMES
Sotalol has a virtually unique antiarrhythmic profile in that it combines the properties of the Class II betablocking agents with the Class III properties that prolong repolarization. The Class II action exerts a marked effect on atrioventricular nodal conduction and makes sotalol a suitable drug fo